Literature DB >> 28148787

The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.

Yong Hu1, Wei Li1, Ting Gao1, Yan Cui1, Yanwen Jin1, Ping Li1, Qingjun Ma1, Xuan Liu2, Cheng Cao2.   

Abstract

Severe acute respiratory syndrome (SARS) is a respiratory disease, caused by a coronavirus (SARS-CoV), that is characterized by atypical pneumonia. The nucleocapsid protein (N protein) of SARS-CoV plays an important role in inhibition of type I interferon (IFN) production via an unknown mechanism. In this study, the SARS-CoV N protein was found to bind to the SPRY domain of the tripartite motif protein 25 (TRIM25) E3 ubiquitin ligase, thereby interfering with the association between TRIM25 and retinoic acid-inducible gene I (RIG-I) and inhibiting TRIM25-mediated RIG-I ubiquitination and activation. Type I IFN production induced by poly I·C or Sendai virus (SeV) was suppressed by the SARS-CoV N protein. SARS-CoV replication was increased by overexpression of the full-length N protein but not N amino acids 1 to 361, which could not interact with TRIM25. These findings provide an insightful interpretation of the SARS-CoV-mediated host innate immune suppression caused by the N protein.IMPORTANCE The SARS-CoV N protein is essential for the viral life cycle and plays a key role in the virus-host interaction. We demonstrated that the interaction between the C terminus of the N protein and the SPRY domain of TRIM25 inhibited TRIM25-mediated RIG-I ubiquitination, which resulted in the inhibition of IFN production. We also found that the Middle East respiratory syndrome CoV (MERS-CoV) N protein interacted with TRIM25 and inhibited RIG-I signaling. The outcomes of these findings indicate the function of the coronavirus N protein in modulating the host's initial innate immune response.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  RIG-I; SARS coronavirus; TRIM25; interferon; nucleocapsid

Mesh:

Substances:

Year:  2017        PMID: 28148787      PMCID: PMC5375661          DOI: 10.1128/JVI.02143-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

Review 1.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist.

Authors:  Ye Ye; Kevin Hauns; Jeffrey O Langland; Bertram L Jacobs; Brenda G Hogue
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR.

Authors:  Laura Gillim-Ross; Jill Taylor; David R Scholl; Jared Ridenour; Paul S Masters; David E Wentworth
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

4.  Multiple nucleic acid binding sites and intrinsic disorder of severe acute respiratory syndrome coronavirus nucleocapsid protein: implications for ribonucleocapsid protein packaging.

Authors:  Chung-Ke Chang; Yen-Lan Hsu; Yuan-Hsiang Chang; Fa-An Chao; Ming-Chya Wu; Yu-Shan Huang; Chin-Kun Hu; Tai-Huang Huang
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

5.  One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities.

Authors:  Lorenzo Subissi; Clara C Posthuma; Axelle Collet; Jessika C Zevenhoven-Dobbe; Alexander E Gorbalenya; Etienne Decroly; Eric J Snijder; Bruno Canard; Isabelle Imbert
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

6.  Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.

Authors:  Yohichi Kumaki; Craig W Day; Miles K Wandersee; Bradley P Schow; Justin S Madsen; Dixon Grant; Jason P Roth; Donald F Smee; Lawrence M Blatt; Dale L Barnard
Journal:  Biochem Biophys Res Commun       Date:  2008-04-10       Impact factor: 3.575

Review 7.  Bat origin of human coronaviruses.

Authors:  Ben Hu; Xingyi Ge; Lin-Fa Wang; Zhengli Shi
Journal:  Virol J       Date:  2015-12-22       Impact factor: 4.099

8.  A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Authors:  Craig W Day; Ralph Baric; Sui Xiong Cai; Matt Frieman; Yohichi Kumaki; John D Morrey; Donald F Smee; Dale L Barnard
Journal:  Virology       Date:  2009-10-22       Impact factor: 3.616

Review 9.  TRIM family proteins: retroviral restriction and antiviral defence.

Authors:  Sébastien Nisole; Jonathan P Stoye; Ali Saïb
Journal:  Nat Rev Microbiol       Date:  2005-10       Impact factor: 60.633

10.  Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

Authors:  Bart L Haagmans; Thijs Kuiken; Byron E Martina; Ron A M Fouchier; Guus F Rimmelzwaan; Geert van Amerongen; Debby van Riel; Ton de Jong; Shigeyuki Itamura; Kwok-Hung Chan; Masato Tashiro; Albert D M E Osterhaus
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more
  124 in total

Review 1.  TRIM Proteins and Their Roles in Antiviral Host Defenses.

Authors:  Michiel van Gent; Konstantin M J Sparrer; Michaela U Gack
Journal:  Annu Rev Virol       Date:  2018-06-27       Impact factor: 10.431

2.  To TRIM or not to TRIM: the balance of host-virus interactions mediated by the ubiquitin system.

Authors:  Adam Hage; Ricardo Rajsbaum
Journal:  J Gen Virol       Date:  2019-12       Impact factor: 3.891

3.  Tripartite motif proteins: an emerging antiviral protein family.

Authors:  Girish Patil; Shitao Li
Journal:  Future Virol       Date:  2019-01-21       Impact factor: 1.831

4.  Paramyxovirus V Proteins Interact with the RIG-I/TRIM25 Regulatory Complex and Inhibit RIG-I Signaling.

Authors:  Maria T Sánchez-Aparicio; Leighland J Feinman; Adolfo García-Sastre; Megan L Shaw
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 5.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

6.  A RIG-I-like receptor directs antiviral responses to a bunyavirus and is antagonized by virus-induced blockade of TRIM25-mediated ubiquitination.

Authors:  Yuan-Qin Min; Yun-Jia Ning; Hualin Wang; Fei Deng
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

Review 7.  Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.

Authors:  Jintao Zhang; Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

8.  Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.

Authors:  Chi-You Chang; Helene Minyi Liu; Ming-Fu Chang; Shin C Chang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

9.  Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.

Authors:  Abigail Vanderheiden; Philipp Ralfs; Tatiana Chirkova; Amit A Upadhyay; Matthew G Zimmerman; Shamika Bedoya; Hadj Aoued; Gregory M Tharp; Kathryn L Pellegrini; Candela Manfredi; Eric Sorscher; Bernardo Mainou; Jenna L Lobby; Jacob E Kohlmeier; Anice C Lowen; Pei-Yong Shi; Vineet D Menachery; Larry J Anderson; Arash Grakoui; Steven E Bosinger; Mehul S Suthar
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

10.  SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2.

Authors:  Jingfang Mu; Yaohui Fang; Qi Yang; Ting Shu; An Wang; Muhan Huang; Liang Jin; Fei Deng; Yang Qiu; Xi Zhou
Journal:  Cell Discov       Date:  2020-09-15       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.